Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1
Portfolio Pulse from Benzinga Newsdesk
Arrowhead Pharmaceuticals has filed for regulatory clearance to initiate a Phase 1 clinical trial of ARO-SOD1, an RNAi-based investigational medicine for treating amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations. ARO-SOD1 is the first therapeutic candidate leveraging Arrowhead's TRiM platform for CNS delivery.
June 27, 2023 | 11:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arrowhead Pharmaceuticals filed for regulatory clearance to begin a Phase 1 trial of ARO-SOD1, a potential ALS treatment using its TRiM platform.
The news of Arrowhead Pharmaceuticals filing for regulatory clearance to initiate a Phase 1 clinical trial of ARO-SOD1 is positive for the company. If approved, it will allow the company to advance its investigational medicine for treating ALS caused by SOD1 mutations. This could potentially lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100